Leta i den här bloggen

torsdag 14 maj 2020

Ensimmäisistä rokotekokeiluista uutisia JPost 14.5. 2020

https://www.jpost.com/health-science/oxford-coronavirus-vaccine-found-protective-in-small-monkey-study-628063

Oxford coronavirus vaccine found protective in small monkey study
British drugmaker AstraZeneca last month announced it had teamed up with researchers at the Oxford Vaccine Group and the Jenner Institute, which are developing the vaccine.
 
 https://images.jpost.com/image/upload/f_auto,fl_lossy/t_JD_ArticleMainImageFaceDetect/457814

 Muita uutisia: 

 https://www.jpost.com/health-science/israeli-disinfectant-kills-100-percent-of-viruses-bacteria-627242
Israeli disinfectant kills 100% of viruses, bacteria
The Israel Institute for Biological Research developed a disinfectant that kills 100% of viruses and bacteria, and is currently being used in mikvehs in Bnei Brak.


 https://www.jpost.com/health-science/iibr-completes-development-phase-of-covid-19-vaccine-626913
Israel's IIBR finds antibody that neutralizes coronavirus
IIBR, Yeroham to collaborate on vaccine production facility


Last month, IIBR announced that it had begun testing a COVID-19 vaccine prototype on rodents. The institute was personally asked by Prime Minister Benjamin Netanyahu to join the fight against the pandemic in early February.
The institute is also involved in plasma collection from people who have recovered from being infected with the new coronavirus, in the hope that this might help research.
MEANWHILE, IIBR and the small southern town of Yeroham on Monday night announced they have big plans to open Israel's first vaccine production facility, in partnership with one of two prospective international pharmaceutical companies, according to a spokesperson for the Yeroham local council.
The Monday night announcement came after a meeting Sunday between the heads of the IIBR, Yeroham’s local council and the CEO of an international pharmaceutical company. A model was presented that would allow for the quick establishment of such a facility, if approved by the Israeli government. 
The facility can reportedly be built "in the very near future," even before IIBR completes full development and approvals for its coronavirus vaccine, which it predicts will be in early 2021.
In 2016, Israel's government adopted decision 120B, which ordered the establishment of a vaccine plant as a strategic asset for the State of Israel in the event of a pandemic, after a decade of discussions on the matter. However, negotiations on the matter had stalled since the decision was made, and no working models had been agreed upon until Monday's announcement.
According to the model, tens of millions of vaccine units of various types will be manufactured in Yeroham, which will ensure Israeli self-sufficiency during both regular routine vaccinations and in case of a pandemic.
While the Yeroham local council plans to provide infrastructure and manpower and IIBR will provide the research aspect of the deal, the model still relies on an undecided third partner for international operations, marketing and distribution purposes.  
Negotiations are currently underway with two of the world's largest international pharmaceutical companies, one from India and the other from the United States. At the same time, in the coming days, they will turn to the Bill and Melinda Gates Fund, which aims to set up vaccination facilities around the world to help find a vaccine for COVID-19.
IIBR is not the only Israeli research team that has shared progress on efforts to develop a vaccine or treatment for the novel virus. MigVax, an affiliate of the MIGAL Galilee Research Institute, recently reported that it is close to completing the first phase of development of a coronavirus vaccine. 
Last week, it secured a $12 million investment from OurCrowd to accelerate the path to clinical trials. The company told The Jerusalem Post that is hopes to begin human trials of its oral vaccine as early as June 1.

https://www.jpost.com/health-science/the-great-coronavirus-vaccine-hacking-arms-race-analysis-628055

Inga kommentarer:

Skicka en kommentar